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The present study was carried out to evaluate the eﬀects of the water extract of Chinese medicine “Pingliu Keli” (PK) on human
glioma cell viability and apoptosis and to investigate its mechanisms of action in SHG-44 cells. MTT assay showed that PK
had a strong cytotoxic eﬀect on SHG-44 cells. The number of live cells was less than 20% after exposure to 90μg/mL PK for
24h. PK increased cytotoxicity of SHG-44 cells in a dose-dependent manner. PK caused arrest of SHG-44 cells in G1 phase at
low concentration and in G2 phase at high concentration. The percentage of apoptotic cells by ﬂow cytometric analysis of the
DNA-stained cells increased to 38% and 52% after treatment with 72 and 108μg/mL PK, respectively. In addition, PK increased
the expression of proapoptotic protein (Bax) and decreased antiapoptotic protein (Bcl-2), with a concomitant increase in the
levels of cleaved caspase-3, cleaved caspase-9 and cleaved poly-ADP-ribose polymerase (PARP). These results suggest that PK
has a signiﬁcant apoptosis inducing eﬀect on SHG-44 glioma cells in vitro and caspase-3 may act as a potential mediator in the
process.
1.Introduction
Up to 65% of primary brain tumors are of glial origin and
these glial-derived tumors are collectively called gliomas.
Glioma is one of the most malignant human tumors [1]
and, despite aggressive surgical resection and radiotherapy,
the median survival in these patients does not normally
exceed one year [1, 2]. The use of systemic chemotherapy
may improve the eﬃcacy of treatment, but its use is asso-
ciated with signiﬁcant toxicity and the long-term prognosis
remains poor [3]. It is now being increasingly recognized
that intervening critical processes of cancer growth and
development with naturally occurring herbal and phyto-
chemical agents to achieve chemoprevention is crucial to
decreasing the morbidity and mortality of these and other
cancers. Chinese herbal medicine has long been used for
treatingmalignancies[4,5].Whereassingleherbsareseldom
used alone, herbal cocktails take advantage of synergy and
interactions among a myriad of phytochemicals present in
the diﬀerent herbs to achieve therapeutic eﬃcacy targeting
multiple biological and pathological processes while min-
imizing side eﬀects [6, 7]. However, herbal remedies are
yet to be integrated into main stream medicine due to
a number of challenges, including herbal standardization
and quality control issues, safety and toxicity concerns,
interactions with existing therapeutic modalities, a lack
of proven eﬃcacy by standard clinical trials and a lack
of mechanistic details, to name a few [8, 9]. Rigorous
in vitro and preclinical animal studies will be essential
and necessary to evaluate their eﬃcacy and safety before
clinical trials can be contemplated for the chemoprevention
and treatment of these major cancers in humans and to
transform traditional herbal practices into “evidence-based
medicine.”
In China, the water decoction of “Pingliu Keli” (PK) is
employed as a folk remedy for the treatment of glioma [10].
The present study examined the antiproliferative activity of
a water extract of PK and its eﬀect on the cell cycle and
apoptosis of SHG-44 glioma cells. Furthermore, the levels of
several important genes that are strongly associated with the
signal transduction pathway of apoptosis were measured to
establish the anticancer mechanism of PK.2 Evidence-Based Complementary and Alternative Medicine
Table 1: The composition of “Pingliu Keli” (PK).
Species Chinese name Plant part Origin Grams %
Lycium chinense Gou Qi Seed Ningxia, China 40 11.1
Dendrobium oﬃcinale Shi hu Stem Yunnan, China 40 11.1
Arisaema heterophyllum Tian nan xing Stem Guizhou, China 40 11.1
Rhizoma typhonii Bai fu zi Stem tuber Tibet, China 40 11.1
Curcuma zedoaria E shu Stem tube Guangxi, China 40 11.1
Ligusticum chuanxiong Chuan xiong Root Sichuan, China 40 11.1
Buthus martensii Karsch Xie zi Dried body Shandong, China 40 11.1
Bombyx mori L Jia can Dried body Jiangsu, China 40 11.1
Herba hedyotis diﬀusae She she cao Leave Yunnan, China 40 11.1
Total amount 360 100
2. Methods
2.1. Materials. DMEM medium, heat-inactivated fetal
bovine serum (FBS), penicillin, and streptomycin were
purchased from Gibco, USA. MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide], DMSO (dimethyl
sulfoxide) were obtained from Sigma, USA. Lysis buﬀer
was purchased from Beyotime, China. Hoechst 33258 was
purchased from KeyGEN, China. FITC Annexin V Apoptosis
Detection Kit was purchased from BD Biosciences, USA.
Antibodies (caspase-3, caspase-9, goat antimouse IgG-HRP,
and goat antirabbit IgG-HRP) were obtained from Santa
Cruz, USA. Bcl-2, Bcl-XL, Bax, PARP antibodies was pur-
chased from Cell Signaling Technology, USA. monoclonal
mouse anti-glyceraldehyde-3-phosphate dehydrogease
(GAPDH) was obtained from KangChen, China.
2.2. Formula Preparation. PK is composed of Lycium chi-
nense (40g), Dendrobium oﬃcinale (40g), Arisaema hetero-
phyllum (40g), Rhizoma typhonii (40g), Curcuma zedoaria
(40g),Ligusticumchuanxiong (40g),ButhusmartensiiKarsch
(40g), Bombyx mori L (40g), and Herba hedyotis diﬀusae
(40g). All medicinal plants used to prepare formulae
were provided by Jiangsu Province Integrated Chinese and
Western Medicine Hospital (Nanjing, China), plant parts,
and origin used in the formula as Table 1. The plant were
homogenized with a waring blender, then soaked in 10 Liter
double distilled water (DDW) for 24h. The mixture was
heated to 100
◦C for 2h, and the decoction was ﬁltrated.
The ﬁltrates obtained from 3 cycles of the procedures
were mixed, concentrated by heating and granulated by
lyophilization. Total yield of the PKextractis 95g lyophilized
powder from water extract of 1kg raw mixed herb. PK and
its preparations were standardized, regulated, and quality-
controlled according to the guidelines deﬁned by Chinese
State Food and Drug Administration (SFDA).
2.3. Cell Culture and Morphological Assessment. The SHG-
44 human glioma cell line was obtained from Cell Bank
of Shanghai Institute of Biochemistry and Cell Biology
(Shanghai, China) and cultured in DMEM medium supple-
mented with 10% heat-inactivated fetal bovine serum (FBS),
100U/mL penicillin and 100μg/mL streptomycin at 37
◦C
and5%CO2.SHG-44cellswereculturedinDMEMmedium
till mid-log phase. Distilled water (control), 36, 54, 7290
or 108μg/mL PK was then added to the culture medium.
The morphology of cells was monitored under an inverted
microscope (Zeiss Axio Observer A1) at 6, 12, 18, 24, and
48h.
2.4. Hoechst 33258 Staining. Hoechst 33258 staining was
used to visualize nuclear changes and apoptotic body
formation. At the end of PK (36, 54, 72, 90, or 108μg/mL)
treatment, attached cells were washed twice with PBS and
ﬁxed with 4% methanal at 4◦C for 30min. The Fixing
solution was removed and cells were washed twice with
PBS before staining with Hoechst 33258. After staining
for 10min, cells were washed again and observed under
a ﬂuorescence microscope (Zeiss Axio Observer A1) at
340nm.
2.5. Cell Viability Assay. MTT was used as an indicator of
cell viability as determined by its mitochondrial-dependent
reduction to formazone. SHG-44 cells were cultured in
DMEM medium till mid-log phase, then seeded in 96-well
plate at a density of 1 × 104 cells per well in 100μLm e d i u m .
After 24h of incubation, cells were exposed to distilled water
(control), 18, 36, 54, 72, 90, or 108μg/mL PK for 24h. After
treatment, 10μLo f5m g / m LM T Tw a sa d d e da n dt h ec e l l s
were incubated further for 4h at 37
◦C. The supernatant was
discarded and 100μL of DMSO was added to each well.
The mixture was shaken on a minishaker at room tem-
perature for 10min and the spectrophotometric absorbance
was measured by Multiskan Spectrum Microplate Reader
(Thermo) at 570nm and 630nm (absorbance 570nm,
reference 630nm). Triplicate experiments were performed
in a parallel manner for each concentration point and the
results were presented as mean±SD. The net A570nm−A630nm
was taken as the index of cell viability. The net absorbance
from the wells of cells cultured with 0.1% DMSO was takenEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Inhibition of the cell growth and induction of apoptosis by PK in human malignant glioma cell SHG-44. After treating with
diﬀerent concentration of PK for 48h, the cells were observed using an inverted microscope (Zeiss Axio Observer A1) or stained with
Hoechst 33258, and then photographed with a ﬂuorescence microscope. Compared to the control cells, cells exposed to PK presented typical
apoptotic morphology with cell shrinkage, nuclear condensation, and formation of apoptotic bodies, with rupture of cells. The Hoechst
33258 dye stained morphologically normal nuclei dimly blue, whereas PK-treated cells demonstrated smaller nuclei with brilliant blue
staining (arrows indicate condensed nuclei).
as the 100% viability value. The percent inhibition of the
treated cells was calculated by the following formula:
%Inhibition
=
[(A570nm−A630nm)control − (A570nm−A630nm)treated]
(A570nm−A630nm)control
×100%.
(1)
2.6. Cell-Cycle Analysis. SHG-44 Cells were plated in six-
well plates at a density of 300,000 per well and allowed
to adhere overnight. Cells were treated with distilled water
(control), 36, 72 or 108μg/mL PK in serum-free medium
for 24h or 36h. Cells were then trypsinized and ﬁxed in
ice cold 70% ethanol and stained with propidium iodide in
PBS. Flowcytometric data were acquired using a FACSCan
analysis system equipped with a FACStation, MAC PowerPC
computer and CellQuest Acquisition software from Becton
Dickinson (FACSCalibur, Becton Dickinson, USA).4 Evidence-Based Complementary and Alternative Medicine
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Figure 2:InhibitoryeﬀectofPKonthecellproliferationofSHG-44
cells. Theresultsshown were themean of three parallel experiments
(triplicate wells) for each concentration point (18, 36, 54, 72, 90, or
108μg/mL) (P<. 05).
2.7. Annexin-V/PI Double-Staining Assay. SHG-44 cells were
treatedwithdistilledwater(control),72or108μg/mLPKfor
24h. Then they were harvested, washed, and resuspended
with PBS. Apoptotic cells were determined with an FITC
Annexin V Apoptosis Detection Kit (BD Biosciences, USA)
according to the manufacturer’s protocol. Brieﬂy, the cells
were washed and subsequently incubated for 15min at room
temperature in the dark in 100μL of 1x binding buﬀer
containing 5μL of Annexin V-FITC and 5μL of propidium
iodide (PI). Afterward, apoptosis was analyzed by ﬂuores-
cence microscope (Zeiss Axio Observer A1) and FACScan
laserﬂowcytometer(FACSCalibur,BectonDickinson,USA).
2.8. Western Blotting Analysis. SHG-44 cells were cultured
in DMEM till mid-log phase and then incubated with
distilled water (control), 36, 72, or 108μg/mL PK for 24h.
Proteins were isolated by lysis buﬀer (Beyotime, China)
and measured using the Nanodrop 1000 Spectrophotometer
(Thermo, USA). Protein samples were separated on 13%
SDS-polyacrylamide gel (SDS-PAGE) and transferred onto
the PVDF membranes (Millipore). Immune complexes were
formed by incubation of the proteins with primary anti-
bodies, Bcl-2, Bcl-XL, Bax, PARP antibodies (Cell Signaling
Technology, USA), caspase-3, caspase-9 antibodies (Santa
Cruz, USA), and monoclonal mouse anti-glyceraldehyde-
3-phosphate dehydrogease(GAPDH) (KangChen, China)
overnight at 4◦C. Blots were washed and incubated for
1h with goat antimouse IgG-HRP or goat antirabbit IgG-
HRP second antibodies (Santa Cruz, USA). Immunoreactive
protein bands were detected with Gel/Chemi Doc System
(Bio-rad, USA).
2.9. Statistical Analysis. Values were expressed as means ±
standard deviations. Value of <0.05 was considered statisti-
cally signiﬁcant.
3. Results
3.1. Cell Morphological Assessment Eﬀect of PK on Cell
Morphology. Diﬀerences in cell morphology were observed
between PK-treated and control cells by light microscopy.
The most conspicuous changes observed in PK-treated cells
included cell shrinkage and extensive detachment of the
cells from the cell culture substratum. These changes, which
were characteristic of cell apoptotic death, became visible
after 12h of PK treatment, but were absent in control
cells. The morphological changes became more remarkable
with increased time of drug treatment. These observations
suggested that cells treated with PK detached from the
substratum and died by apoptosis (Figure 1(a)).
The occurrence of apoptosis was further veriﬁed by
Hoechst staining, which detects chromatin condensation,
one of the hallmarks of apoptotic cell death. Some dif-
ferences were observed in the nuclei of PK-treated and -
untreated SHG-44 cells after staining with Hoechst 33258
(Figure 1(b)). The Hoechst 33258 dye stained morpholog-
ically normal nuclei dimly blue whereas PK-treated cells
demonstrated smaller nuclei with brilliant blue staining.
The changes in nuclear morphology were initially observed
after 24h of PK treatment and increased thereafter. These
results demonstrate that PK induces morphological changes
characteristic of apoptotic cell death.
3.2. Eﬀects of PK on the Cell Proliferation of SHG-44. To
test the eﬀect of PK on the proliferation of SHG-44 cells,
the cells were treated with diﬀerent concentrations of PK.
After 48h incubation, the cell viability was measured by
MTT assay. PK treatment signiﬁcantly inhibited the growth
of SHG-44 cells, the number of viable cells decreases as the
concentration of PK increases (Figure 2). The eﬀect of PK
treatment is statistically signiﬁcant when compared with the
control group (P<. 05).
3.3. Diﬀerent Eﬀects of Low and High Concentration of PK on
SHG-44 Cell Cycle. Analysis of cell-cycle phase distribution
was carried out to study the antiproliferative mechanism of
PK. Diﬀerent concentration of PK has diﬀerent eﬀects on
SHG-44 cell-cycle. At lower doses of PK (72μg/mL), the
number of SHG-44 cells during G0/G1 was increased, and
the S phase was reduced dramatically. However, when the
concentration was up to108μg/mL, most cells were arrested
at G2/M phase. The cell-cycle arrest was evident at 24h
treatment, and many cells died after 36 h treatment of high
concentration of PK. These results indicated that PK could
inhibit SHG-44 cells synthesizing DNA at low concentration,
whereas high concentration of PK induced G2 arrest by
inhibiting DNA synthesis and cell division (Figure 3).
3.4. Quantiﬁcation of Apoptosis by Flow Cytometry with
Annexin V/PI Staining. Additional evidence for the occur-
rence of apoptosis was obtained by double staining of the
cultures with propidium iodide (which stains the nuclei of
dead cells) and annexin V-FITC, a protein that binds with
high aﬃnity to phosphatidylserine, which is translocatedEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Representative histograms depicting cell-cycle distribution in SHG-44 cell cultures treated with distilled water (control) or various
concentrationsofPKfordiﬀerentperiodoftime.72μg/mLPKinducedG1phasearrestandreducedSphasewhereasmostcellswerearrested
at G2/M phase at 108μg/mL. All data presented were representatives of at least three independent experiments, P<. 05.
from the inner to the outer membrane leaﬂet early in the
apoptotic process. Control cells stained negative for both
propidium iodide and annexin V-FITC. PK-induced cells,
on the other hand, showed many annexin V-positive cells.
The majority of the cells were negative for propidium iodide,
indicating that they were at an early stage of apoptosis.
The double positive staining of particular cells revealed that
these cells were at a late apoptotic (or necrotic) stage. Take
together, these ﬁndings provide strong evidence that PK
induced cell death through apoptosis (Figure 4).
3.5. Western Blot Analysis of PARP, Caspase-3, Caspase-
9, Bax, and Bcl-2/XL Protein. A f t e re x p o s u r ew i t hP Ka t
diﬀerent concentration for 48h, total cell lysate was prepared
and an equal amount of protein was subjected to SDS-
PAGE. Western blot analyses were done with anti-PARP,
-caspase-3, -caspase-9, Bcl-2, Bcl-XL,B a x ,a n dG A P D H
primary antibodies as described in materials and methods.
PK increased the expression of proapoptotic protein (Bax)
and decreased antiapoptotic protein (Bcl-2, Bcl-XL), with a
concomitant increase in the levels of caspase-3, caspase-9
and cleaved poly-ADP-ribose polymerase (PARP) in SHG-
44 after treatment for 48h (Figure 5). These data showed
that PK induced SHG-44 cells apoptosis through a caspase
dependent pathway (Figure 6).
4. Discussion
Malignant gliomas are the most common primary brain
tumors. The patients with malignant gliomas remain6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Annexin-V/PI double-staining assay. After treating with PK, cells were stained with annexin V-FITC and propidium iodide and
analyzed by ﬂuorescence microscopy. Flow cytometric analysis of annexin V-FITC/PI double-staining: SHG-44 cells were left untreated
or treated for 24h with 72 or 108μg/mL PK. Cells were incubated with Annexin V-FITC in a buﬀer containing propidium iodide (PI)
and analyzed by ﬂow cytometry. Untreated cells were primarily Annexin V-FITC and PI negative, indicating that they were viable and not
undergoing apoptosis. After treatment, there were primarily three populations of cells: cells that were viable and not undergoing apoptosis
(Annexin V-FITC and PI negative), cells undergoing apoptosis (Annexin V-FITC positive and PI negative) and population of cells were
observed to be Annexin V-FITC and PI positive, indicating that they were in end stage apoptosis or already dead. (red: stained with Annexin
V-FITC, green: stained with PI, mixture: stained with Annexin V-FITC and PI both).
poorly responsive to multimodality therapeutic interven-
tions, including surgery, radiotherapy, and chemotherapy
[11,12].Ithasbeenreportedthattumorgrowthisdependent
on not only the rate of cellular proliferation, but also that
of cell death [13]. Dysregulation of apoptosis contributes
directly to tumor development and progression including
brain tumors [14–16]. In addition, neoplastic cells’ loss
of the ability to undergo apoptosis is an important factor
that determines the response to treatment with radio- or
chemotherapy [17, 18].
SHG-44 human glioma cell line was derived from a
patient diagnosed with a most malignant and highly invasive
grade IV glioma, known as GBM, and is frequently used as
a model system to study invasive properties of gliomas in
many studies. In the present paper, we demonstrated that
PK inhibited the glioma tumor growth and induced the
apoptosis of SHG-44 glioma cells. Hoechst 33258 staining
and FACS analysis demonstrated that the majority of the
glioma cell death is due to apoptosis, and the diﬀerence
betweencelldeathandapoptosismayresultfromnonspeciﬁc
cell death. To gain insight into the molecular mechanism
involved in apoptosis by PK, expression of apoptotic-related
proteins, Bcl-2, Bcl-XL, Bax, and caspase-3, were assessed
in SHG-44 glioma cells. We showed that the induction of
apoptosis was accompanied by the down-regulation of Bcl-
2 gene expression and up-regulation of Bax gene expression,
suggesting that alteration of Bcl-2 and Bax is directly or
indirectly involved in the apoptotic eﬀect of PK in SHG-44
cells. The expression ratio of proapoptotic and antiapoptotic
genes may determine whether a cell lives or dies following
an insult [19]. Overexpression of Bcl-2 protects cells from
apoptosis following exposure to a number of diﬀerent
proapoptotic stimuli [20], whereas overexpression of Bax
renders cells more sensitive to proapoptotic stimuli [21].
Similarly,wealsofoundthatPKtreatmentcausesadecreased
Bcl-2 expression and increased level of Bax, which may be
responsible for the induction of apoptosis in SHG-44 glioma
cells. It has been reported that the ICE/caspase family playsEvidence-Based Complementary and Alternative Medicine 7
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Figure 5: Expression of apoptosis-related proteins in PK-treated cells. The left panel denotes the eﬀect of distilled water (control) and the
right panel represents the results of 36μg/mL, 72μg/mL and 108μg/mL PK after exposure for 48h. Data shown were representatives of at
least three independent experiments.
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Figure 6: Regulation of the intrinsic apoptotic pathway by PK. The active compounds of PK reduced their eﬀectiveness after digesting
and absorbing by patients. PK increased the expression of proapoptotic protein (Bax) and decreased antiapoptotic protein (Bcl-2, Bcl-XL),
with a concomitant increase in the levels of caspase-3, caspase-9 and cleaved poly-ADP-ribose polymerase (PARP) in SHG-44 cells. Caspase
dependent cell death was the possible mechanism of PK’s antitumor activity.
a crucial role in apoptosis [22]. In particular, caspase-3
has been shown to be a key component of the apoptotic
machinery [23–25]. Our data demonstrated that caspase-3
was activated by PK, indicating that caspase-3 might be one
of the critical steps in PK-induced apoptosis.
5. Conclusion
This study clearly demonstrates that the water extract of PK
strongly inhibits cell proliferation and induces apoptosis in
SHG-44 cells. PK induced apoptosis through the activation8 Evidence-Based Complementary and Alternative Medicine
of caspases-9 and -3 and degradation of PARP. Because
apoptosis was regarded as a new target in discovery of
anticancer drugs, these results conﬁrm the potential of PK
as an agent of chemotherapeutic and cytostatic activity in
human glioma cells. Although PK is most commonly used
in Chinese medicine, the mechanistic aspects of its eﬀects
are still unknown and potential of its bioactive components
are yet to be recognized [25, 26]. Thus, evaluation and
characterization of the water-soluble active components
for discovery of potentially safe glioma-therapeutic phyto-
reagents is warranted.
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